|
Real-time Estimate
Cboe BZX
11:03:55 2026-08-17 EDT
|
5-day change | 1st Jan Change | ||
| 13.64 USD | +1.45% |
|
+2.96% | +96.67% |
| 08-06 | B. Riley Adjusts COMPASS Pathways Price Target to $22 From $17, Maintains Buy Rating | MT |
| 08-06 | RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.86B | - | - | - | - | - |
| 48.42B | |||||
| 43.66B | - | - | - | - | - |
| 39.51B | |||||
| 38.95B | |||||
| 32.61B |
- Stock Market
- Stocks
- CMPS Stock
- Charts COMPASS Pathways plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
